Skip to main content
SpringerLink
Log in

ATTR: Diagnosis, Prognosis, and Treatment

  • Chapter
  • First Online:
Amyloidosis

Part of the book series: Contemporary Hematology ((CH))

Abstract

ATTR is the most common form of inherited systemic amyloidosis. The signs and symptoms of ATTR are often subtle and overlap with more common diseases, including AL. Treatment for ATTR is most effective early in the course of the disease, making timely diagnosis critical. Orthotopic liver transplantation is the only proven effective therapy. Recent reports have suggested that amyloid deposition may progress after liver transplantation in some cases. Emerging therapies designed to prevent circulating TTR from forming amyloid are currently being tested and hold promise for patients not eligible for solid organ transplant and for those with progressive symptoms after transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–23.

    Article  PubMed  CAS  Google Scholar 

  2. Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc. 1992;67(5): 428–40.

    Article  PubMed  CAS  Google Scholar 

  3. Comenzo RL, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins[see comment]. Blood. 2006;107(9):3489–91.

    Article  PubMed  CAS  Google Scholar 

  4. Lachmann HJ, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis[see comment]. N Engl J Med. 2002;346(23):1786–91.

    Article  PubMed  CAS  Google Scholar 

  5. Bergen HR 3rd, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis [see comment]. Clin Chem. 2004;50(9):1544–52.

    Article  PubMed  CAS  Google Scholar 

  6. Nepomuceno AI, et al. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry [see comment]. Clin Chem. 2004;50(9):1535–43.

    Article  PubMed  CAS  Google Scholar 

  7. Altland K, et al. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis. 2007;28(12):2053–64.

    Article  PubMed  CAS  Google Scholar 

  8. Rosenzweig M, et al. A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. Amyloid. 2007;14(1):65–71.

    Article  PubMed  CAS  Google Scholar 

  9. Picken MM, Herrera GA. The burden of “sticky” amyloid: typing challenges [see comment]. Arch Pathol Lab Med. 2007;131(6):850–1.

    PubMed  Google Scholar 

  10. Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol. 2006;30(6):673–83.

    Article  PubMed  Google Scholar 

  11. Satoskar AA, et al. Typing of amyloidosis in renal biopsies: diagnostic pitfalls.[see comment]. Arch Pathol Lab Med. 2007;131(6):917–22.

    PubMed  Google Scholar 

  12. Murphy CL, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48–62.

    Article  PubMed  CAS  Google Scholar 

  13. Bellavia D, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol. 2008;101(7):1039–45.

    Article  PubMed  Google Scholar 

  14. Bellavia D, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007;20(10):1194–202.

    Article  PubMed  Google Scholar 

  15. Dispenzieri A, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.

    Article  PubMed  CAS  Google Scholar 

  16. Suhr OB, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med. 2008;263(3):294–301.

    Article  PubMed  CAS  Google Scholar 

  17. Perugini E, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006;92(3):343–9.

    Article  PubMed  CAS  Google Scholar 

  18. Perugini E, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanoldicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84.

    Article  PubMed  Google Scholar 

  19. Hazenberg BPC, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119(4):355.e15–24.

    Article  PubMed  Google Scholar 

  20. Afolabi I, et al. Transthyretin isoleucine-122 mutation in African and American blacks. Amyloid. 2000;7(2):121–25.

    Article  PubMed  CAS  Google Scholar 

  21. Jacobson DR, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.[see comment]. N Engl J Med. 1997;336(7):466–73.

    Article  PubMed  CAS  Google Scholar 

  22. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057–62.

    Article  PubMed  Google Scholar 

  23. Lobato L. Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). J Nephrol. 2003;16(3):438–42.

    PubMed  CAS  Google Scholar 

  24. Oguchi K, Takei Y-I, Ikeda S-I. Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients. Amyloid. 2006;13(2):99–107.

    Article  PubMed  CAS  Google Scholar 

  25. Lobato L, et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid. 2004;11(1):27–37.

    Article  PubMed  Google Scholar 

  26. Tashima K, et al. Gastrointestinal dysfunction in familial amyloidotic polyneuropathy (ATTR Val30Met)–comparison of Swedish and Japanese patients. Amyloid. 1999;6(2):124–9.

    Article  PubMed  CAS  Google Scholar 

  27. Steen L, Ek B. Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Medica Scandinavica. 1983;214(5):387–97.

    Article  PubMed  CAS  Google Scholar 

  28. Galvan-Guerra E, et al. Diagnostic utility of serum beta-carotenes in intestinal malabsorption syndrome. Revista de Investigacion Clinica. 1994;46(2):99–104.

    PubMed  CAS  Google Scholar 

  29. Falls HF, et al. Ocular manifestations of hereditary primary systemic amyloidosis. AMA. Arch Ophthalmol. 1955;54(5):660–64.

    Article  CAS  Google Scholar 

  30. Tsukahara S, Matsuo T. Secondary glaucoma accompanied with primary familial amyloidosis. Ophthalmologica. 1977;175(5):250–62.

    Article  PubMed  CAS  Google Scholar 

  31. Ong DE, et al. Synthesis and secretion of retinol-binding protein and transthyretin by cultured retinal pigment epithelium. Biochemistry. 1994;33(7):1835–42.

    Article  PubMed  CAS  Google Scholar 

  32. Ando Y, et al. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004;77(3):345–49.

    Article  PubMed  CAS  Google Scholar 

  33. Munar-Ques M, et al. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid. 2000;7(4):266–9.

    Article  PubMed  CAS  Google Scholar 

  34. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–27.

    Article  PubMed  CAS  Google Scholar 

  35. Block WD, Curtis AC, Rukavina JG. Familial primary systemic amyloidosis: an experimental, genetic and clinical study. J Invest Dermatol. 1956;27(3):111–31.

    PubMed  CAS  Google Scholar 

  36. Husby G. Nomenclature and classification of amyloid and amyloidoses. J Intern Med. 1992;232(6):511–2.

    Article  PubMed  CAS  Google Scholar 

  37. Andersson R. Hereditary amyloidosis with polyneuropathy. Acta Medica Scandinavica. 1970;1–2(1):85–94.

    PubMed  Google Scholar 

  38. Misu KI, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951–62.

    Article  PubMed  Google Scholar 

  39. Sobue G, et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid. 2003;10(Suppl 1):32–8.

    PubMed  CAS  Google Scholar 

  40. Ducla-Soares J, et al. Correlation between clinical, electromyographic and dysautonomic evolution of familial amyloidotic polyneuropathy of the Portuguese type. Acta Neurol Scand. 1994;90(4):266–9.

    Article  PubMed  CAS  Google Scholar 

  41. Ellie E, et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology. 2001;57(1):135–37.

    Article  PubMed  CAS  Google Scholar 

  42. Goren H, Steinberg MC, Farboody GH. Familial oculoleptomeningeal amyloidosis. Brain. 1980;103(3):473–95.

    Article  PubMed  CAS  Google Scholar 

  43. Petersen RB, et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol. 1997;41(3):307–13.

    Article  PubMed  CAS  Google Scholar 

  44. Ushiyama M, Ikeda S, Yanagisawa N. Transthyretin-type cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. Acta Neuropathol. 1991;81(5):524–8.

    Article  PubMed  CAS  Google Scholar 

  45. Riisoen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer’s disease. Acta Neurol Scand. 1988;78(6):455–9.

    Article  PubMed  CAS  Google Scholar 

  46. Serot JM, et al. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatr. 1997;63(4):506–8.

    Article  PubMed  CAS  Google Scholar 

  47. Hammarstrom P, et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry. 2003;42(22):6656–63.

    Article  PubMed  Google Scholar 

  48. Holmgren G, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clinical Genetics. 1991;40(3):242–6.

    Article  PubMed  CAS  Google Scholar 

  49. Results from the Familial World Transplant Registry. Available from: http://www.fapwtr.org/ram_fap.htm. Accessed 30 June 2008 [cited 2009 June 1]

  50. Herlenius G, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77(1):64–71.

    Article  PubMed  Google Scholar 

  51. Adams D, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(Pt 7):1495–504.

    Article  PubMed  Google Scholar 

  52. Shimojima Y, et al. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol. 2008;255(8):1220–5.

    Article  PubMed  Google Scholar 

  53. Bergethon PR, et al. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology. 1996;47(4):944–51.

    Article  PubMed  CAS  Google Scholar 

  54. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004;17(5):615–20.

    Article  PubMed  Google Scholar 

  55. Sharma P, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl. 2003;9(12):1273–80.

    Article  PubMed  Google Scholar 

  56. Suhr OB, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation. 1995;60(9):933–38.

    Article  PubMed  CAS  Google Scholar 

  57. Pomfret EA, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation. 1998;65(7):918–25.

    Article  PubMed  CAS  Google Scholar 

  58. Olofsson B-O, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002;73(5):745–51.

    Article  PubMed  Google Scholar 

  59. Stangou AJ, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66(2):229–33.

    Article  PubMed  CAS  Google Scholar 

  60. Hornsten R, et al. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation. 2004;78(1):112–16.

    Article  PubMed  Google Scholar 

  61. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid. 2007;14(4): 277–82.

    Article  PubMed  CAS  Google Scholar 

  62. Yazaki M, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7(1): 235–42.

    Article  PubMed  CAS  Google Scholar 

  63. De Carolis P, et al. Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis. Neurol Sci. 2006;27(5):352–4.

    Article  PubMed  CAS  Google Scholar 

  64. Mascalchi M, et al. Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology. 1999;53(7):1498–503.

    Article  PubMed  CAS  Google Scholar 

  65. Azoulay D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. 1999;189(6):584–93.

    Article  PubMed  CAS  Google Scholar 

  66. Furtado A, et al. Sequential liver transplantation. Transplant Proc. 1997;29(1–2):467–8.

    Article  PubMed  CAS  Google Scholar 

  67. Schmidt HH, et al. Familial Amyloidotic Polyneuropathy: domino liver transplantation. J Hepatol. 1999;30(2):293–8.

    Article  PubMed  CAS  Google Scholar 

  68. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005;352(22):2356.

    Article  PubMed  CAS  Google Scholar 

  69. Takei Y-I, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver.[see comment]. Liver Transpl. 2007;13(2):215–18.

    Article  PubMed  Google Scholar 

  70. Coelho T, et al. A strikingly benign evolution of FAP in an individual compound heterozygote for two TTR mutations: TTR Met30 and TTR Met119. J Rheumatol. 1993; 20:179.

    Google Scholar 

  71. Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459–62.

    Article  PubMed  CAS  Google Scholar 

  72. Hammarstrom P, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299(5607):713–6.

    Article  PubMed  Google Scholar 

  73. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–49.

    Article  PubMed  CAS  Google Scholar 

  74. Waddington-Cruz M, et al. A landmark clinical trial of a novel small molecule transthyretin (TTR) stabiliser, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II/III, randomised, double-blind, placebo-controlled study. J Neurol. 2008;255(Suppl 2):107.

    Google Scholar 

  75. Wolf G. Retinol transport and metabolism in transthyretin-”knockout” mice. Nutr Rev. 1995;53(4 Pt 1):98–9.

    PubMed  CAS  Google Scholar 

  76. Benson MD, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33(5):609–18.

    Article  PubMed  CAS  Google Scholar 

  77. Tanaka K, et al. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci. 2001;183(1):79–84.

    Article  PubMed  CAS  Google Scholar 

  78. Nakamura M, et al. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Therpy. 2004;11(10):838–46.

    Article  CAS  Google Scholar 

  79. Cardoso I, Merlini G, Saraiva MJ. 4ʹ-iodo-4ʹ-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003;17(8):803–09.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Steven R. Zeldenrust MD, PhD

Authors
  1. Steven R. Zeldenrust MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Zeldenrust, S.R. (2010). ATTR: Diagnosis, Prognosis, and Treatment. In: Gertz, M., Rajkumar, S. (eds) Amyloidosis. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-631-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-631-3_14

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-630-6

  • Online ISBN: 978-1-60761-631-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation